GlassScriptPhysician profile
James R Bellor
NPI 1710905377
$16,364.01
in general payments reported to CMS, 2019-2025
35 companies · $2,795 in 2025
The $2,795 reported for 2025 was more than what 75% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,706 · 2020: $1,520 · 2021: $2,193 · 2022: $1,656 · 2023: $3,044 · 2024: $2,451 · 2025: $2,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,987 · Education: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,986.96 |
| Education | $302.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,158.25 | 2019-2025 | Evenity, Enbrel, Prolia |
| Abbvie INC. | $2,991.70 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $2,592.14 | 2019-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $1,921.65 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $1,101.95 | 2019-2025 | |
| Pfizer INC. | $812.18 | 2019-2025 | |
| Lilly USA, LLC | $591.91 | 2019-2024 | Taltz |
| Mallinckrodt Hospital Products INC. | $528.24 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $371.70 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $358.29 | 2019-2024 | Benlysta |
| Janssen Scientific Affairs, LLC | $339.28 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $292.49 | 2019-2025 | Orencia |
| Aurinia Pharma U.S., INC. | $196.65 | 2022-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.73 | 2023-2024 | Cyltezo, Ofev |
| Horizon Therapeutics Plc | $149.51 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Health Care Systems INC. | $104.72 | 2023 | Stelara |
| Genentech USA, INC. | $99.49 | 2021-2025 | Actemra |
| Genzyme Corporation | $88.93 | 2020-2024 | |
| Regeneron Healthcare Solutions, INC. | $67.94 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $64.84 | 2019 | |
| Sandoz INC. | $60.36 | 2023-2024 | Hyrimoz |
| Radius Health, INC. | $59.81 | 2019-2025 | |
| Celgene Corporation | $41.86 | 2019 | |
| Fresenius Kabi USA, LLC | $39.05 | 2024 | Idacio |
| Kowa Pharmaceuticals America, INC. | $30.45 | 2023 | Seglentis |
| Alexion Pharmaceuticals, INC. | $20.58 | 2025 | Strensiq |
| Mylan Institutional INC. | $19.84 | 2023 | Hulio |
| Assertio Therapeutics, INC. | $19.33 | 2019 | |
| Fidia Pharma USA INC. | $15.29 | 2021 | |
| Bioventus LLC | $15.26 | 2020 | |
| Eisai INC. | $15.11 | 2020 | |
| Hikma Pharmaceuticals USA | $14.75 | 2019 | |
| Merck Sharp & Dohme LLC | $13.68 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.05 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bellor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.